teclistamab,daratumumab
janssen,genmab
['mmsm', 'daratumumab', 'majestec-1', 'teclistamab']
sbcma and t-cell status can help predict outcomes of bispecific antibody treatment- correlative studies from majestec-1 #ash22 #mmsm 
MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.